Data / Drug companies / Etoposide
Etoposide: 9 companies and 18 products in the FDA NDC directory
Etoposide is listed in the FDA National Drug Code Directory by 9 companies, with 18 products in commercial distribution. 14 of the products (77.8%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection; injection, solution, concentrate; capsule, and the newest product started marketing on September 14, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 9
- Products
- 18
- Generic (ANDA) products
- 14 (77.8%)
- Application numbers
- 7
- Routes
- Intravenous, Oral
- Brand names
- VePesid, Avopef
- openFDA record search
- api.fda.gov
Companies that list etoposide
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| BluePoint Laboratories | 4 | injection, solution, concentrate; injection | Generic drugs (ANDA) | December 1, 2025 |
| Hikma Pharmaceuticals USA Inc. | 4 | injection | Generic drugs (ANDA) | February 1, 1997 |
| Meitheal Pharmaceuticals Inc. | 3 | injection, solution, concentrate | Generic drugs (ANDA) | February 1, 2025 |
| Avyxa Pharma, LLC | 2 | injection | New drug applications (NDA) | September 14, 2026 |
| Accord Healthcare Inc. | 1 | injection | Generic drugs (ANDA) | March 3, 2015 |
| Amneal Pharmaceuticals NY LLC | 1 | capsule | Authorized generics (NDA) | May 15, 2026 |
| Fresenius Kabi USA, LLC | 1 | injection, solution | Generic drugs (ANDA) | July 18, 2001 |
| Mylan Pharmaceuticals Inc. | 1 | capsule | Generic drugs (ANDA) | October 22, 2001 |
| Onesource Specialty Pharma Limited | 1 | capsule | New drug applications (NDA) | May 29, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 8 | 44.4% |
| Injection, solution, concentrate | 6 | 33.3% |
| Capsule | 3 | 16.7% |
| Injection, solution | 1 | 5.6% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 14 | 77.8% |
| New drug applications (NDA) | 3 | 16.7% |
| Authorized generics (NDA) | 1 | 5.6% |
Pharmacologic classes
| Class | Products |
|---|---|
| Topoisomerase Inhibitor | 18 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.